Table 2.
General characteristics of the subjects according to the cancer status.
| AC (n = 46) | RC (n = 33) | WC (n = 534) | p | |
|---|---|---|---|---|
| Demographic data | ||||
| Age, years | 73.2 ± 11.2 | 74.4 ± 11.1 | 72.5 ± 13.1 | 0.665 |
| Males, n (%) | 25 (54.3) | 19 (57.6) | 289 (54.1) | 0.928 |
| Vascular risk factors | ||||
| Previous TIA/stroke, n (%) | 6 (13) | 1 (3) | 53 (9.9) | 0.321 |
| Cardiovascular disease, n (%) | 4 (8.7) | 7 (21.2) | 77 (14.4) | 0.292 |
| Atrial fibrillation, n (%) | 9 (19.6) | 8 (24.2) | 97 (18.2) | 0.674 |
| Hypertension, n (%) | 33 (71.7) | 26 (78.8) | 354 (66.3) | 0.267 |
| Diabetes mellitus, n (%) | 7 (15.2) | 6 (18.2) | 93 (17.4) | 0.922 |
| Hypercholesterolemia, n (%) | 15 (32.6) | 14 (42.4) | 133 (24.9) | 0.053 |
| Current smoking, n (%) | 8 (17.4) | 5 (15.2) | 74 (13.9) | 0.794 |
| Laboratory findings | ||||
| Hb, g/dl | 12.8 ± 1.8 | 13.5 ± 1.5 | 13.1 ± 1.7 | 0.151 |
| Platelets, 103/mm3 | 186.5 ± 65 | 186.8 ± 40.3 | 205.4 ± 60.2 | 0.052 |
| aPTT ratio* | 0.95 (0.88–1.04) | 0.93 (0.86–1.07) | 0.95 (0.87–1.08) | 0.897 |
| INR* | 1.06 (1.01–1.11) | 1.04 (1–1.16) | 1.06 (1–1.14) | 0.868 |
| C-reactive protein, mg/l* | 9.89 (2.57–14.35) | 3.11 (1.28–9.04) | 4.37 (1.95–11.68) | 0.059 |
| Protein, g/dl | 6 ± 0.6 | 6.3 ± 0.4 | 6.2 ± 0.6 | 0.045 |
| Albumin, g/dl | 3.6 ± 0.4 | 3.6 ± 0.3 | 3.7 ± 0.4 | 0.312 |
| Glucose, mg/dl* | 124.5 (105.2–144.5) | 115 (106–137) | 126 (109–155) | 0.181 |
| eGFR, ml/mina | 84.6 ± 20.9 | 84.1 ± 26.1 | 78.3 ± 24 | 0.111 |
| Total cholesterol, mg/dl* | 164 (138–190) | 164 (139–193) | 172 (146–200) | 0.723 |
| HDL cholesterol, mg/dl | 51.5 ± 17.8 | 51.1 ± 14.6 | 52.9 ± 15.9 | 0.723 |
| LDL cholesterol, mg/dl | 94.9 ± 31.1 | 96.8 ± 34.8 | 100.3 ± 37.4 | 0.594 |
| Triglycerides, mg/dl* | 88 (70–131) | 102 (79–135) | 93 (67.5–126) | 0.691 |
| Blood pressure and heart rate | ||||
| Systolic blood pressure, mmHg | 157.8 ± 22.8 | 163 ± 27 | 157.1 ± 24.9 | 0.447 |
| Diastolic blood pressure, mmHg | 89.2 ± 13.5 | 90.2 ± 14.7 | 86.6 ± 15.1 | 0.273 |
| Heart rate, min | 76.2 ± 15 | 77.4 ± 14.1 | 78.3 ± 15.7 | 0.716 |
| Antithrombotic treatment at admission | 0.646 | |||
| Antiplatelets, n (%) | 15 (32.6) | 15 (45.5) | 180 (33.7) | |
| Anticoagulants, n (%) | 2 (4.3) | 2 (6.1) | 37 (6.9) | |
| Median baseline ASPECTS (range) | 10 (8–10) | 10 (8–10) | 10 (7–10) | 0.901 |
| Stroke subtypes based on TOAST classification | 0.692 | |||
| Large arterial atherosclerosis, n (%) | 5 (10.9) | 7 (21.2) | 83 (15.5) | |
| Cardioembolism, n (%) | 21 (45.7) | 14 (42.4) | 209 (39.1) | |
| Small vessel occlusion, n (%) | 3 (6.5) | 4 (12.1) | 48 (9) | |
| Other determined etiology, n (%) | 0 | 0 | 14 (2.6) | |
| Undetermined etiology, n (%) | 17 (37) | 8 (24.2) | 180 (33.7) | |
| Baseline clinical characteristics | ||||
| Median NIHSS score at admission (IQR) | 12.5 (6–20) | 9 (5–17) | 9 (5–18) | 0.128 |
| Median NIHSS score at discharge (IQR) | 3.5 (0.2–10) | 1 (0–8.5) | 2 (0–8) | 0.318 |
| Pre-stroke mRS 0–2, n (%) | 43 (93.5) | 31 (93.9) | 480 (89.9) | 0.566 |
| Type of recanalization therapy | 0.089 | |||
| IVT, n (%) | 24 (54.3) | 25 (75.8) | 390 (73) | |
| MT + IVT, n (%) | 13 (28.3) | 6 (18.2) | 95 (17.8) | |
| MT, n (%) | 8 (17.4) | 2 (6.1) | 49 (9.2) | |
| Other information on recanalization therapy | ||||
| Time from symptoms onset to IVT, min | 172 ± 57.3 | 180.3 ± 59.9 | 164.5 ± 49.5 | 0.063 |
| Time from symptoms onset to MT, min | 191 ± 46.8 | 215 ± 37.2 | 213.5 ± 70.3 | 0.456 |
| Door-to-needle time, min | 76.2 ± 15 | 77.4 ± 14.1 | 78.3 ± 15.7 | 0.257 |
| Door-to-groin time, min* | 123.5 (105.7–143.2) | 112.5 (85.5–137.2) | 105 (80–135) | 0.281 |
| MT procedure length, min | 79.9 ± 36.2 | 72.5 ± 35.5 | 77.1 ± 38.9 | 0.892 |
| TICI 2b-3 after MT, n (%) | 15 (71.4) | 5 (62.5) | 119 (82.6) | 0.207 |
Data are presented as mean and standard deviation for normally distributed continuous variables. Non-normally distributed continuous variables are displayed as median and interquartile range and are identified by an asterisk (*).
AC active cancer, RC remote cancer, WC without cancer, TIA transient ischemic attack, Hb haemoglobin, aPTT activated partial thromboplastin time, INR international normalised ratio, eGFR estimated glomerular filtration rate, HDL high-density lipoprotein, LDL low-density lipoprotein, ASPECTS Alberta stroke program early CT score, NIHSS National Institute of Health stroke scale, IQR interquartile range, mRS modified Rankin scale, IVT intravenous thrombolysis, MT mechanical thrombectomy, TICI thrombolysis in cerebral infarction.
aeGFR was calculated using the Modification of Diet in Renal Disease formula.